Dr. Giulia Biancon is an Assistant Professor Adjunct in the Department of Medical Oncology and Hematology at Yale School of Medicine. She holds a PhD from the University of Milan (2019) and is a member of the Halene Lab, focusing on RNA biology and hematologic malignancies. Her research combines high-throughput methodologies to study RNA mechanisms in diseases like myeloid leukemias and splicing factor mutations. Education: PhD in Molecular Biology from the University of Milan (2019). Research Interests: RNA splicing, stress granules in cancer, epitranscriptomics, clonal hematopoiesis, and the interplay between genetic mutations and cellular pathways in blood cancers. Awards: 2024 Eclipse Award, 2022 ASH Abstract Achievement Award, and 2022 RNA Society Best Poster Award. Her work has been published in journals like Cell Reports , Blood , and Molecular Cell . Labs/Teams: Principal member of the Halene Lab and coordinator at the Yale Center for RNA Science and Medicine. Collaborates with institutions like the SeroNet network for immunology studies.
Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.
Dr. Vakil Takhaveev is a Lecturer at ETH Zurich's Department of Health Sciences and Technology, within the Institute of Food, Nutrition and Health. His research focuses on DNA damage mechanisms, aging, cancer, and neurodegeneration, with particular emphasis on developing novel DNA-damage-sequencing methods like click-code-seq and TRABI-Seq . He investigates anticancer drug action (e.g., trabectedin), aging clocks using DNA oxidation profiling, and stress-induced carcinogenesis. His work integrates multi-omics approaches and advanced sequencing techniques. Research Directions: Novel DNA-Damage-Sequencing Methods: Developed click-code-seq and TRABI-Seq for genomic mapping of DNA lesions and repair dynamics. Anticancer Drug Action: Explored mechanisms of trabectedin and other chemotherapeutics, linking DNA repair vulnerabilities to therapy resistance. Aging Clocks: Created DNA oxidation-based biomarkers for biological aging using genome-wide profiling in human and mouse models. Stress-Induced Pathologies: Studies metabolic and DNA damage links to early tumorigenesis and neurodegeneration. Awards & Recognition: 2025 Public Award Winner in PIs of Tomorrow competition 2024 ETH Zurich Career Seed Award Best presentation awards (Swiss Chemical Society, American Chemical Society) Grants & Collaborations: Impetus grants for aging clock development Swiss Chemical Society and American Chemical Society fellowships Labs & Teams: Leads research on DNA damage and aging mechanisms at ETH Zurich, collaborating with international groups in oncology and toxicology.
David Vocadlo is a Distinguished Professor of Chemistry and Molecular Biology & Biochemistry at Simon Fraser University (SFU), holding the Canada Research Chair in Chemical Biology. His research focuses on Chemical Glycobiology, investigating carbohydrate-processing enzymes and developing chemical tools to study glycan roles in health and disease. His lab explores O-GlcNAc signaling, neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s), and enzyme inhibitors for therapeutic applications. Education: PhD from University of British Columbia (UBC), followed by a CIHR postdoctoral fellowship at UC Berkeley. Key roles include E.W.R. Steacie Memorial Fellow and Royal Society Fellow. Research highlights include O-GlcNAcase inhibitors for neuroprotection, glycan structure-function relationships, and enzyme activity imaging tools. Collaborates globally with experts in glycobiology and employs cutting-edge techniques like chemical synthesis, mass spectrometry, and live-cell imaging. Awards: Distinguished Professor title, Canada Research Chair, Royal Society Fellowship. Active in training researchers through SFU’s graduate programs, emphasizing interdisciplinary approaches. Lab members work on topics ranging from enzyme mechanisms to disease modeling.
Zhe Ji is an Assistant Professor in the Department of Biomedical Engineering at McCormick School of Engineering and the Department of Pharmacology at Feinberg School of Medicine, Northwestern University. His research integrates computational and experimental genomics to study gene transcription and RNA translation in cell fate commitment and oncogenic processes, aiming to develop precision medicine strategies. **Education**: Postdoctoral Fellow in Cancer Systems Biology, Harvard Medical School Postdoctoral Fellow in Computational Biology, Broad Institute of MIT and Harvard Ph.D. in Computational Genomics, Rutgers University B.S. in Biotechnology, Nanjing University, China **Research Focus**: Keywords include Data Science, Computational Biology, Functional Genomics, RNA, Cancer, Inflammation, and Machine Learning. The lab explores regulatory mechanisms underlying disease, with a focus on translational control, cancer metastasis, and inflammatory networks. **Grants & Advising**: No specific grants or student advisees listed. The lab emphasizes collaborative projects and computational-experimental approaches. **Lab Affiliations**: Zhe Ji’s lab is part of Northwestern’s interdisciplinary environment, bridging engineering and medicine to advance genomic technologies and therapeutic strategies.
Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788
Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.
Michael Lampson is Professor of Biology at the University of Pennsylvania's School of Arts and Sciences, with secondary appointments in the Department of Cell and Developmental Biology. He serves as faculty in the Cell and Molecular Biology (CAMB) and Biochemistry and Molecular Biophysics (BMB) Graduate Groups, and is affiliated with the American Society for Cell Biology (ASCB). Ph.D., Cornell University, Weill Medical College, 2002 AB, Harvard College, 1994 Dr. Lampson's research program focuses on fundamental mechanisms of chromosome biology, with particular emphasis on cell division, centromere inheritance, and meiotic drive. His lab investigates how selfish genetic elements can violate Mendel's First Law through meiotic drive, the stability of centromere chromatin through the germline, and the role of repetitive satellite DNA in chromosome segregation. Using innovative approaches including mouse model systems, optogenetic tools, and biochemical techniques, his work bridges cell biology, genetics, and evolutionary biology to address questions with implications for reproductive biology, cancer, and genetic inheritance. Analysis of Dr. Lampson's recent publications reveals a strong focus on the intersection of centromere biology, meiotic drive, and chromosome segregation mechanisms. His work increasingly incorporates computational approaches alongside experimental systems to study evolutionary aspects of centromere function. The research demonstrates consistent innovation in methodology, particularly in developing optogenetic tools for precise manipulation of cellular processes. Key themes include the role of satellite DNA variation, mechanisms of non-Mendelian inheritance, and the stability of chromatin structures through cell division and development. Searle Scholar Award American Association for the Advancement of Science (AAAS) fellow Dr. Lampson's research is supported by multiple NIH grants including from NIGMS, NHGRI, NICHD, and NCI, as well as University of Pennsylvania funding sources including the University Research Foundation, Abramson Cancer Center, and several specialized research centers. He collaborates extensively with researchers across disciplines, including Ben Black (Biochemistry), Dennis Discher (Chemical Engineering), Dave Chenoweth (Chemistry), and Roger Greenberg (Cancer Biology), reflecting the interdisciplinary nature of his work. His lab has trained numerous graduate students and postdocs who have gone on to successful careers in academia and industry. The Lampson Lab maintains state-of-the-art facilities for cell biological, genetic, and biochemical research, with specialized equipment for live-cell imaging, optogenetic manipulation, and mouse genetics. The lab fosters a collaborative environment that bridges molecular, cellular, and evolutionary perspectives on chromosome biology.
Christopher E. Nelson is an Assistant Professor in the Department of Biomedical Engineering at the University of Arkansas, College of Engineering. His lab focuses on developing biologically inspired strategies for controlled drug and gene delivery, particularly in the context of gene therapy and regenerative medicine. He is actively supported by the NIH, DoD, and Arkansas Bioscience Institute. Education: Postdoctoral Fellow – Duke University Ph.D. – Vanderbilt University B.S. – University of Arkansas Research Focus: Dr. Nelson’s lab integrates genome editing technologies with targeted delivery systems to address challenges in treating genetic diseases and promoting tissue regeneration. Major themes include CRISPR/Cas9 delivery , gene regulation in wound healing , and safe-harbor genome integration in skeletal muscle. His work spans viral and non-viral delivery vehicles , including lipid nanoparticles and AAV vectors, with a strong emphasis on preclinical validation in models of Duchenne muscular dystrophy and inflammatory disease. Scientific Awards: Controlled Release Society Postdoctoral Fellowship The Hartwell Foundation Postdoctoral Fellowship NIH Pathway to Independence Award (K99/R00) Funding & Support: The Nelson Lab is currently funded by: NIH NIGMS R35 DoD CDMRP DMD IDEA Award Arkansas Bioscience Institute University of Arkansas Engineering & Honors Colleges Lab & Team: The Nelson Lab is a dynamic, interdisciplinary team working at the intersection of gene editing, biomaterials, and regenerative medicine. They regularly present at national conferences such as ASGCT and NCUR, and mentor undergraduate researchers through SURF and Honors College grants.
Lin He is the Thomas and Stacey Siebel Distinguished Chair in Stem Cell Research and Professor of Cell Biology and Physiology at the University of California, Berkeley. His laboratory focuses on understanding the biological functions of non-coding RNAs in development and disease, with particular emphasis on microRNAs (miRNAs) in cancer, stem cell biology, and developmental processes. He developed the CRISPR-EZ method for highly efficient mouse genome editing, significantly advancing genetic research. Research interests include miRNAs' roles in tumor progression, metastasis, and pluripotency regulation in stem cells. His work bridges mouse genetics, genomics, and molecular biology to uncover mechanisms governing non-coding RNA functions. Current projects address miRNAs in oncogenesis, stem cell fate determination, and the interplay between non-coding RNAs and retrotransposons in development. Key contributions include identifying miRNA networks in cancer pathways, demonstrating miRNA requirements for ciliogenesis and lung development, and advancing CRISPR-based genome editing techniques. His interdisciplinary approach integrates genetic, genomic, and cellular tools to explore fundamental questions in biology and medicine. Lab website: helabucb.org CRISPR-EZ technology enables 100% genome editing efficiency in mouse zygotes Pioneering studies on miRNA regulation of PTEN, p53, and oncogene pathways
Preet Singh is a Professor and Associate Chair for Graduate Studies in the School of Materials Science and Engineering at Georgia Tech, with affiliations to the College of Engineering. His research focuses on corrosion science, electrochemistry, and environmental degradation of materials, particularly metals and alloys. Prior to joining Georgia Tech in 2003, he was a faculty member at the Institute of Paper Science and Technology (IPST), where he investigated corrosion issues in the pulp and paper industry. Professor Singh's work explores fundamental mechanisms of material degradation in industrial environments, aiming to develop mitigation strategies against environment-induced failures. Key research areas include corrosion fatigue, hydrogen embrittlement, stress corrosion cracking, and oxidation behavior. His group employs experimental approaches to study material reliability under varying chemical and mechanical conditions. Recent publications demonstrate interdisciplinary collaboration across oncology, agriculture, and energy systems, reflecting broad applications of materials science principles. Research trends show increased focus on biomedical materials and sustainable technologies alongside core corrosion studies. Professor Singh advises graduate students including Abdullah Alzubail, Yousif Al Rabie, Sai Shreeya, Yara, and Sean Li. He directs the Corrosion and Materials Reliability Laboratory (CMCRL), which partners with industry to solve practical engineering challenges related to material performance.
Foteini Mourkioti is an Associate Professor at the University of Pennsylvania's Perelman School of Medicine , with a joint appointment in the Graduate Groups of Cell and Molecular Biology and Bioengineering . She co-directs the Musculoskeletal Regeneration Program at the Penn Institute of Regenerative Medicine and leads the McKay Orthopaedic Research Laboratory . Research Interests : Muscle Stem Cell Biology Mechanobiology Muscle Regeneration Telomere Biology in Muscular Diseases Fibrodysplasia Ossificans Progressiva (FOP) Cardiomyopathy and Aging Key Research Contributions : Developed the Pax7EGFP mouse model for real-time muscle stem cell tracking Discovered telomere shortening as a critical factor in Duchenne Muscular Dystrophy Elucidated the role of NF-κB in muscle stem cell dysfunction Identified Piezo1's role in stem cell morphological states Characterized fibro-adipogenic progenitor dynamics in FOP Scientific Awards : NIH/NHLBI R01 grant recipient (2019) NASA grant awardee (2020, 2017) American Heart Association grant (2017) Muscular Dystrophy Association grant (2019) University Research Foundation grant (2018) Publications & Collaborations : Over 25 publications in high-impact journals like Science Advances , Nature Protocols , and Cell Reports . Collaborates with Penn Cardiovascular Institute and Pennsylvania Muscle Institute.
Bruce Clurman, MD, PhD, serves as Executive Vice President, Chief Scientific Officer, and Deputy Director of Fred Hutchinson Cancer Center. He holds the Rosput Reynolds Endowed Chair and is a Professor in both the Translational Science and Therapeutics Division and Human Biology Division at Fred Hutch, with additional appointments as Professor in the University of Washington Department of Medicine and Adjunct Professor in Pathology. His educational background includes: BA in Philosophy, University of Virginia (1981) PhD in Viral Oncology, Cornell University Graduate School of Medical Sciences (1988) MD, Cornell University Medical College (1989) Residency at Brigham and Women’s Hospital, Boston Fellowship in Medical Oncology/Molecular Medicine at Fred Hutch and UW Dr. Clurman's research centers on cell cycle regulation and protein degradation mechanisms in cancer development. His lab investigates how ubiquitin-proteasome system dysregulation—particularly involving Fbw7 tumor suppressor, cyclin E, CDK2, and Wee1 kinases—drives oncogenesis. Current work focuses on exploiting DNA replication stress and mutations in cell cycle regulators to develop targeted therapies that selectively kill cancer cells while sparing healthy tissue. His major scientific recognitions include: W. M. Keck Foundation Distinguished Young Scholar (1999) National Cancer Institute Clinical Investigator Award José Carreras Fellowship James S. McDonnell Foundation Scholarship Election to American Society for Clinical Investigation (2005) As leader of the Clurman Lab, he directs multidisciplinary research integrating biochemistry, proteomics, and genetically engineered mouse models. He actively contributes to Fred Hutch's Immunotherapy, Pathogen-Associated Malignancies, and Translational Data Science Integrated Research Centers while maintaining clinical practice in blood cancer transplantation.
Istvan Mody is a Professor at the University of California, Los Angeles (UCLA) with appointments in the Department of Neurology and Department of Physiology . His research focuses on synaptic signaling in health and disease, including mechanisms of GABAergic transmission, calcium homeostasis, and their roles in neurological disorders such as epilepsy, Alzheimer's disease, Huntington's disease, stress, alcoholism, and postpartum depression. He utilizes advanced techniques like patch-clamp electrophysiology, neuroanatomical and immunohistochemical methods, and molecular biology in animal models and human brain tissue . Research Interests: Dr. Mody investigates the physiology, pharmacology, and pathology of synaptic transmission and extrasynaptic receptor activation , with a particular emphasis on GABA(A) receptors and their subunit-specific modulation. His work explores how disruptions in excitation-inhibition balance contribute to neurological diseases, including mechanisms of tonic inhibition , calcium signaling , and neurosteroid interactions . He also studies the effects of chronic stress and hormonal fluctuations on neural excitability and behavior. Publications Trends: Recent studies highlight his work on gamma oscillations in Alzheimer's models, microglial dynamics , and rehabilitation strategies for stroke. His lab develops optical tools like dqGEVI for neuronal activity monitoring and investigates human brain organoids to model network dysfunction in epilepsy and intellectual disability. Laboratory Location: 635 Charles Young Dr S, Los Angeles, CA 90095, United States.
Hang Lu is an Associate Professor in the Department of Communication and Media at the University of Michigan's College of Literature, Science, and the Arts. He specializes in science, health, environmental, and risk communication (ComSHER), with a focus on media psychology. His research explores audience responses to media messages about sensitive topics and strategies to enhance message effectiveness. Lu holds a Ph.D. in Communication from Cornell University (2018), along with advanced degrees from Cornell, Marquette University, and Central South University in China. He directs the Media and Risk (MaR) Lab and previously served as a postdoctoral fellow at the Annenberg Public Policy Center. His research spans four main areas: 1) emotion dynamics in media responses, 2) predictors of information behaviors, 3) media effects on stigmatization, and 4) AI applications in sensitive domains. He has published in journals like Journal of Communication , Risk Analysis , and Public Understanding of Science , earning multiple top paper awards. As Vice Chair of the Environmental Communication Division at the International Communication Association, Lu contributes to interdisciplinary dialogue. His work addresses critical societal issues such as climate change communication, vaccination hesitancy, and emerging technology ethics.
